Astellas Pharma Inc. (4503.T)
| Previous close | 1,513.50 |
| Open | 1,509.00 |
| Bid | 1,484.50 x 0 |
| Ask | 1,487.50 x 0 |
| Day's range | 1,481.00 - 1,510.50 |
| 52-week range | 1,426.00 - 2,360.50 |
| Volume | |
| Avg. volume | 8,570,125 |
| Market cap | 2.714T |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 554.85 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 74.00 (4.98%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- PR Newswire
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the cou
- PR Newswire
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA. The newly built 154,000-square-foot lab and office facility expands the company's commitment to South San Francisco's biotech ecosystem and creates a central location for its West Coast employees across Research, Technical Operations, Medical and Development and Commercial, previously located i
- PR Newswire
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
